{"log_id": 6420249186305687811, "direction": 0, "words_result_num": 32, "words_result": [{"probability": {"variance": 2.3e-05, "average": 0.998272, "min": 0.972632}, "location": {"width": 815, "top": 229, "height": 32, "left": 208}, "words": "建议在开始治疗前以及使用富马酸替诺福韦二吡呋酯治疗期间临床上适当时对所有患"}, {"probability": {"variance": 5e-06, "average": 0.998784, "min": 0.987544}, "location": {"width": 819, "top": 260, "height": 28, "left": 209}, "words": "者进行肌酐清除率计算。对有肾功能损害风险的患者,包括先前在接受阿德福韦酯治"}, {"probability": {"variance": 1e-06, "average": 0.999401, "min": 0.995598}, "location": {"width": 726, "top": 291, "height": 26, "left": 208}, "words": "疗时经历过肾脏不良事件的患者,应定期监测计算出的肌酐清除率和血清磷"}, {"probability": {"variance": 0.010109, "average": 0.69883, "min": 0.598289}, "location": {"width": 25, "top": 261, "height": 59, "left": 1139}, "words": "节附"}, {"probability": {"variance": 0.001414, "average": 0.988552, "min": 0.783535}, "location": {"width": 824, "top": 350, "height": 28, "left": 208}, "words": "建议对所有肌酐清除率低于50mL/分钟的患者调整富马酸替诺福韦二吡呋酯的给药间"}, {"probability": {"variance": 2.5e-05, "average": 0.997344, "min": 0.979494}, "location": {"width": 823, "top": 377, "height": 30, "left": 207}, "words": "期,并密切监测其肾功能(参见“用法用量”)。在按照剂量调整指导接受富马酸替诺"}, {"probability": {"variance": 9e-06, "average": 0.998975, "min": 0.981766}, "location": {"width": 816, "top": 406, "height": 29, "left": 207}, "words": "福韦二吡呋酯治疗的肾功能损害患者中,目前还没有可用的安全性或疗效数据,所以"}, {"probability": {"variance": 1e-06, "average": 0.999325, "min": 0.995857}, "location": {"width": 793, "top": 437, "height": 27, "left": 207}, "words": "应当对接受富马酸替诺福韦二吡呋酯治疗的潜在受益和肾毒性的潜在风险进行评估"}, {"probability": {"variance": 1.4e-05, "average": 0.998437, "min": 0.977002}, "location": {"width": 814, "top": 496, "height": 27, "left": 208}, "words": "如果目前或近期曾使用过有肾毒性的制剂,应当避免使用富马酸替诺福韦二吡呋酯治"}, {"probability": {"variance": 0, "average": 0.999171, "min": 0.999171}, "location": {"width": 24, "top": 527, "height": 25, "left": 207}, "words": "疗"}, {"probability": {"variance": 0, "average": 0.999406, "min": 0.998613}, "location": {"width": 159, "top": 579, "height": 27, "left": 208}, "words": "与其他药物联用"}, {"probability": {"variance": 0.000164, "average": 0.996577, "min": 0.924008}, "location": {"width": 749, "top": 608, "height": 27, "left": 208}, "words": "富马酸替诺福韦二吡呋酯不应与含有替诺福韦的固定剂量复方制剂联用,包括"}, {"probability": {"variance": 0.000395, "average": 0.988396, "min": 0.921126}, "location": {"width": 433, "top": 637, "height": 27, "left": 272}, "words": "依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯"}, {"probability": {"variance": 0.004649, "average": 0.979895, "min": 0.679996}, "location": {"width": 432, "top": 667, "height": 26, "left": 273}, "words": "利匹韦林/恩曲他滨/富马酸替诺福韦二吡呋酯"}, {"probability": {"variance": 0.005041, "average": 0.974512, "min": 0.714598}, "location": {"width": 570, "top": 693, "height": 30, "left": 273}, "words": "艾维雷韦/克比司特/恩曲他滨/富马酸替诺福韦二吡呋酯,或"}, {"probability": {"variance": 1e-06, "average": 0.99921, "min": 0.997571}, "location": {"width": 183, "top": 724, "height": 27, "left": 272}, "words": "恩曲他滨替诺福韦"}, {"probability": {"variance": 0.00016, "average": 0.995435, "min": 0.926141}, "location": {"width": 761, "top": 779, "height": 28, "left": 208}, "words": "富马酸替诺福韦二吡呋酯不应与阿德福韦酯联合给药(参见“药物相互作用”)。"}, {"probability": {"variance": 0.003305, "average": 0.970259, "min": 0.817137}, "location": {"width": 301, "top": 828, "height": 28, "left": 209}, "words": "HIV1和HBV合并感染的患者"}, {"probability": {"variance": 0.000703, "average": 0.991857, "min": 0.856947}, "location": {"width": 818, "top": 857, "height": 28, "left": 209}, "words": "因存在HIV-1耐药风险,富马酸替诺福韦二吡呋酯仅可作为抗逆转录病毒联合治疗方"}, {"probability": {"variance": 0.000764, "average": 0.986346, "min": 0.898803}, "location": {"width": 431, "top": 887, "height": 27, "left": 211}, "words": "案的一部分用于HBV和HV-1合并感染患者"}, {"probability": {"variance": 0.001162, "average": 0.990587, "min": 0.832515}, "location": {"width": 806, "top": 941, "height": 26, "left": 208}, "words": "所有HBV感染患者开始富马酸替诺福韦二吡呋酯治疗前应进行HIV-1抗体检查。也"}, {"probability": {"variance": 0.009864, "average": 0.976335, "min": 0.422477}, "location": {"width": 793, "top": 969, "height": 28, "left": 209}, "words": "建议所有HV-1感染患者开始富马酸替诺福韦二吡呋酯治疗前进行慢性乙肝的检查"}, {"probability": {"variance": 6e-06, "average": 0.998076, "min": 0.991808}, "location": {"width": 181, "top": 1025, "height": 27, "left": 209}, "words": "骨矿物质密度下降"}, {"probability": {"variance": 3e-06, "average": 0.999131, "min": 0.992373}, "location": {"width": 789, "top": 1073, "height": 28, "left": 210}, "words": "在有病理性骨折或有骨硬化症或有骨流失风险的成人及12或12岁以上儿童患者中"}, {"probability": {"variance": 5e-06, "average": 0.998811, "min": 0.987826}, "location": {"width": 818, "top": 1103, "height": 27, "left": 210}, "words": "应当考虑骨监测。尽管没有对补充钙和维生素D的作用进行研究,但这样的补充可能"}, {"probability": {"variance": 5.4e-05, "average": 0.997239, "min": 0.962671}, "location": {"width": 594, "top": 1133, "height": 26, "left": 209}, "words": "对所有患者都有益。如果怀疑有骨异常,应当进行适当的会诊"}, {"probability": {"variance": 0, "average": 0.998766, "min": 0.997739}, "location": {"width": 89, "top": 1220, "height": 27, "left": 212}, "words": "成人患者"}, {"probability": {"variance": 3.4e-05, "average": 0.99759, "min": 0.966147}, "location": {"width": 811, "top": 1268, "height": 28, "left": 211}, "words": "在研究903的144周期间,试验的两个治疗组中都发现接受过富马酸替诺福韦二吡呋"}, {"probability": {"variance": 0.000577, "average": 0.987755, "min": 0.905131}, "location": {"width": 893, "top": 1296, "height": 39, "left": 210}, "words": "酯治疗的HIV感染的成人受试者中,腰椎和髋部的骨密度(BMD)相对于基线下降。"}, {"probability": {"variance": 0.007284, "average": 0.974249, "min": 0.530828}, "location": {"width": 767, "top": 1324, "height": 29, "left": 211}, "words": "在第144周,与接受司他夫定十拉米夫定+依非韦伦的受试者相比(-1.0%±4.6"}, {"probability": {"variance": 0.005903, "average": 0.971865, "min": 0.549755}, "location": {"width": 942, "top": 1330, "height": 92, "left": 209}, "words": "基线值的下降平均百分比明显较高(22%土39)。这两个治疗组中髋部骨密度的变"}, {"probability": {"variance": 0.012829, "average": 0.970645, "min": 0.49337}, "location": {"width": 815, "top": 1352, "height": 29, "left": 211}, "words": "接受富马酸替诺福韦二吡呋酯十拉米夫定十依非韦伦治疗的受试者腰椎骨密度相对于"}], "language": 3}